Communiqués Sun Pharmaceutical Industries Ltd. Bombay S.E.

Actions

SUNPHARMA

INE044A01036

Produits pharmaceutiques

Marché Fermé - Bombay S.E. 12:02:29 09/10/2026			Varia. 5j.	Varia. 1 janv.
1 756,90 ^INR	+0,25 %		-2,93 %	+2,16 %

08/10	Viatris va acquérir Pacira BioSciences pour 1,65 milliard de dollars	MT
07/10	Sun Pharmaceuticals envisage de lever 1,55 milliard de dollars via des obligations	RE

Communiqués

07/10	Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care	AQ
24/09	Sun Pharma Launches (C)Taro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System	AQ
08/05	Sun Pharma To Acquire Organon	AQ
28/04	India’s Sun Pharma agrees all cash takeover of Organon	AQ
02/03	Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami	AQ
16/01	Sun Pharma Announces the Availability of UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma	AQ
02/01	Sun Pharma Launches ILUMYA® In India	AQ
01/12	Sun Pharma introduces its global innovative drug, Ilumya in India for treatment of moderate-to-severe Plaque Psoriasis	AQ
14/07/25	Delhi HC Rejects CBDT's Endeavor Of Prescribing Limitation Through A Circular In The Absence Of Statutory Backing	AQ
16/06/25	Sun Pharma appoints Kirti Ganorkar as the Managing Director, Dilip Shanghvi to continue as the Executive Chairman of the Board	AQ
12/06/25	Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.	AQ
25/04/25	Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage	AQ
25/11/24	Healthcare \| July And August 2024 - Case Laws	AQ
28/10/24	Sun Pharma Presents LEQSELVI Data Highlighting Clinical Efficacy and Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference	AQ
02/10/24	Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for commercializing the specialty product FIBROMUN	AQ
09/09/24	Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain	AQ
17/06/24	Sun Pharma - Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis	AQ
23/05/24	Taro Shareholders Approve Merger with Sun Pharma	AQ
27/09/23	Sun Pharma Canada Launches (PR)WINLEVI® (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne	AQ
14/09/23	Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi in India	AQ
26/06/23	Sun Pharma Announces Health Canada Approval of (PR)ABSORICA LD® (isotretinoin capsules) for Treatment of Severe Nodular Acne	AQ
31/05/23	Sun Pharma Announces China NMPA Approval for ILUMETRI for Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	AQ
31/05/23	Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY in Europe, Australia and New Zealand	AQ
21/11/22	Sun Pharmaceutical Industries Limited - SEZABY approved by US FDA for the treatment of neonatal seizures	AQ
23/03/22	Sun Pharmaceutical Industries : Litigations/Disputes/Regulatory actions	PU